



Composition of the Gut Microbiota in Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis

Ning Wang^{1†}, Xuping Gao^{1†}, Zifeng Zhang^{2*} and Li Yang^{1,2*}

¹ Department of Child and Adolescent Psychiatry, National Clinical Research Center for Mental Disorders and NHC Key Laboratory of Mental Health (Peking University Sixth Hospital), Peking University Sixth Hospital (Institute of Mental Health), Beijing, China, ² Department of Psychiatry, Yan'an Third People's Hospital, Yan'an, China

OPEN ACCESS

Edited by:

Cristina Giaroni, University of Insubria, Italy

Reviewed by:

Valentina Caputi, University College Cork, Ireland Ilia Bresesti, University of Insubria, Italy

*Correspondence:

Li Yang yangli_pkuimh@bjmu.edu.cn Zifeng Zhang zhangzifeng113@126.com

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Translational Endocrinology, a section of the journal Frontiers in Endocrinology

Received: 20 December 2021 Accepted: 17 February 2022 Published: 18 March 2022

Citation:

Wang N, Gao X, Zhang Z and Yang L (2022) Composition of the Gut Microbiota in Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis. Front. Endocrinol. 13:838941. doi: 10.3389/fendo.2022.838941 **Background:** The latest research accumulates information to explore the correlation between gut microbiota and neurodevelopmental disorders, which may lead to new approaches to treat diseases such as attention deficit/hyperactivity disorder (ADHD). However, the conclusions of previous studies are not completely consistent. The objective of the systematic review and meta-analysis was to identify evidence on the dysbiosis of gut microbiota in ADHD and find potential distinctive traits compared to healthy controls.

Methods: Electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, and PsycINFO, were searched up to August 24, 2021, using predetermined terms. Meta-analysis was performed to estimate the comparison of microbiota profiles (alpha and beta diversity) and the relative abundance of gut microbiota in ADHD patients and healthy controls.

Results: A total of eight studies were included in the meta-analysis, containing 316 ADHD patients and 359 healthy controls. There was a higher Shannon index in ADHD patients than in healthy controls (SMD = 0.97; 95% Cl, 0.13 to 1.82; P = 0.02; $l^2 = 96\%$), but the significance vanished after sensitivity analysis because of high heterogeneity. No significant differences in other alpha diversity indexes were found. Regarding the relative abundance of gut microbiota, the genus *Blautia* was significantly elevated in ADHD patients compared with controls (SMD = 0.34; 95% Cl, 0.06 to 0.63; P = 0.02; $l^2 = 96\%$).

Conclusions: Patients with ADHD had gut microbiome alterations compared to healthy controls. Though more studies with strict methodology are warranted due to the high heterogeneity, further studies to translate the findings of gut microbiota dysbiosis to clinical application in ADHD patients are needed and may guide targeted therapies.

Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=273993], identifier PROSPERO (CRD42021273993).

Keywords: attention-deficit/hyperactivity disorder, gut microbiota, dysbiosis, *Blautia*, systematic review and meta-analysis

INTRODUCTION

ADHD is one of the most common neurodevelopmental disorders and onset in early childhood, with a prevalence of 5.9% worldwide (1). It is a clinically heterogeneous disease that manifests with different combinations of symptoms, including inattention, hyperactivity, impulsivity, cognitive impairment, and imposes huge burdens on patients and families. The etiologies of ADHD are multifactorial, including genetic (2) and environmental (3) components.

ADHD patients usually have gastrointestinal symptoms (4) such as constipation, abdominal pain, fecal incontinence, accompanied by picky eating (5), and many other diseases (4–6) such as food allergies, asthma, and eczema. All these symptoms have been documented to be influenced by gut microbiota. Possible mechanisms involved microbial metabolites, amino acid metabolites, immune factors, and neurotransmitters (7).

Currently, the major therapeutic interventions for ADHD are medications, behavioral therapy, and cognitive training. While the efficacy of stimulant medications is validated by powered clinical trials, side effects, including decreased appetite, slight sleep delay, and cardiovascular risks, remain a cause for concern. In recent years, researchers have emphasized the importance of environmental factors such as the gut microbiota to investigate novel therapeutic approaches, including probiotics and prebiotics.

To date, several systematic reviews have shown the correlation between ADHD and gut microbiota, but no metaanalysis has been conducted. Thus, we performed this systematic review and meta-analysis to investigate the relationship between ADHD and gut microbiota and find potential distinctive traits in ADHD.

MATERIALS AND METHODS

Protocol and Registration

The study was registered in PROSPERO (CRD42021273993) and strictly followed the PRISMA guidelines (8).

Study Eligibility Criteria

Studies were included based on the following PICOS criteria.

Participants

Participants with confirmed ADHD were selected for the review, irrespective of age, gender, race, the existence of co-morbidities, and the use of medication. Animal studies were excluded in the review.

Interventions, Exposure(s)

No specific exposure was required. We were not interested in interventional studies.

Comparators

Comparator group was healthy controls (HCs) without ADHD diagnosis.

Outcomes

Studies were eligible if they report the differences between ADHD patients and HCs in gut microbiota diversity indices (alpha diversity and beta diversity) and relative or absolute abundance of microbial taxa.

Study Design

Studies were included if they were observational studies or controlled trials. Studies were excluded if they met any of the following criteria: case reports, conference presentations, reviews, expert opinions, or study protocol.

Search Strategy

The most commonly used databases, including PubMed, Embase, Web of Science, Cochrane Library, and PsycINFO, were searched up to August 24, 2021, using the predetermined terms. The search strategy used is available in **Supplementary Material 1**. We did not set restrictions on language, year, or geographical location. Moreover, we manually searched the reference lists of identified articles to find potentially relevant studies and searched the System for Information on Grey Literature in Europe (SEGLE) and WorldCat for grey literature.

Two individual reviewers (NW, XPG) screened the titles and abstracts independently for possible articles. If there was an agreement between the two reviewers regarding a particular study, it was selected for further analysis; however, if there was disagreement, a third reviewer (LY) would determine whether the study qualifies for inclusion. The full texts of these potentially eligible studies were independently evaluated for eligibility by three reviewers (NW, XPG, ZFZ). Any disagreement between them was resolved by discussion or by a third reviewer (LY) when required.

Data Extraction

If studies met the criteria mentioned above, then the data were extracted by one independent reviewer (NW) using a standardized extraction form. The second author (LY) will review all the extracted data with the team to resolve disputes, and the group (NW, XPG, ZFZ, LY) will finalize the data.

For all eligible studies, the following information was extracted: first author; year of publication; country; number, age and sex of ADHD patients as well as healthy controls; definition of ADHD; alpha diversity (microbial diversity within the same group's samples, including observed operational taxonomic units (OTUs), observed species, Shannon diversity, Chao1 diversity, Simpson diversity); beta diversity (community diversity between different groups' samples, including weighted UniFrac distances, unweighted UniFrac distances, Bray–Curtis distance, Jaccard distance); data on microbiota (including the phyla, order, family, genera, and species of microbiota detected and the methodology used for the microbiology assessment); dietary assessment; probiotics usage assessment.

Quality Assessment

The quality of eligible studies was assessed using the Newcastle– Ottawa Quality Assessment Scale (NOS) (9) and evaluated by two reviewers (NW, XPG). The NOS assessed the quality of studies based on selection, comparability, and exposure, with a total score ranging from 0 to 9. A study of greater than 7 points is defined as a high-quality study.

Data Synthesis

Different studies have investigated the gut microbiota's taxonomic composition at different levels, such as phylum, order, family, genus and species, with a large number and limited overlap of findings. We excluded results if they were reported only in one study.

Data Analysis

Studies included in this meta-analysis reported the comparison of gut microbiota between ADHD patients and controls, including alpha diversity and the relative abundance of bacteria of different phyla, families, and genera. These data were extracted from texts, figures, and supplementary materials. If only figures were given, we used Webplot-digitizer software (https://automeris.io/WebPlotDigitizer/) to extract these parameters from the graphs. Most data are expressed as the means \pm standard deviations, and the others are presented as medians and interquartile ranges. We standardized all the data into the form of means \pm standard deviations for subsequent analyses using a web-based tool (https://www.math.hkbu.edu.hk/ ~tongt/papers/median2mean.html).

This meta-analysis was undertaken using Review Manager 5.4 software. Data of gut microbiota were expressed as standardized mean difference (SMD). Heterogeneity was measured using I^2 statistics, with I^2 >50% indicating significant heterogeneity. A fixed-effect model was used for initial analyses, and a random effect model was used if I^2 >50%. Sensitivity analyses excluding one study at a time were conducted when the heterogeneity was high, but subgroup analyses and meta-regression were not conducted because of limited literature. Two-sided *P* values were statistically significant if *P*<0.05. Potential publication biases were detected by funnel plots. Given to the limited capacity of funnel plots when pooling a small number of trials, we further preformed Egger's test to verify the potential publication bias.

RESULTS

Search Results

Up to August 24, 2021, 593 records were found after searching the five databases, and 502 were retained after duplicate manual removal. After screening the title and abstract, 488 studies were removed because of dissatisfaction with the inclusion criteria. After reviewing the full texts of the remaining articles, three were excluded because of a lack of insufficient data, and one was excluded because the data of microbiota is not for gut microbiota. Finally, eight eligible studies were included in this systematic review and meta-analysis (**Figure 1**), and the PRISMA report is presented in **Supplementary Material 2**.

Study Characteristics

Table 1 summarizes the characteristics of the eight studies included in the meta-analysis, among which four were conducted in China (including Taiwan) (12–14, 17), two in the Netherlands (10, 15), one in Germany (11) and one in Spain (16). A total of 316 ADHD patients and 359 healthy controls were included in the analysis, and the sample sizes ranged from 14 to 100. Most studies were age- and gender-matched, and there were no significant differences in demographics, except the study by Aarts, in which the HCs had 39 older adults and caused an older mean age (10). For participants, four studies were conducted in children (12–14, 17), one was in children and adolescents (11), two were in adolescents and adults (10, 15), and the last was in adults (16).

For the clinical diagnosis of ADHD, six studies were assessed according to DSM-IV (10–13, 15, 16), and others followed DSM-5 (14, 17). For the assessment of microbiology, except the one conducted by Wan et al. (14) that used shotgun metagenomics (14), other studies used 16S rRNA gene sequencing (10–13, 15–17). Likewise, there were three pipeline analyses in the included studies, QIIME (10, 12, 17), Mothur (11, 13), and Bowtie2 (14), except for two examinations that did not specify the analyses (15, 16).

We also take care of ADHD medication because it may cause gut microbiota disorders. Three of the included records consisted of medication-naïve participants to compare ADHD patients and HCs (12, 13, 16), one study asked patients to discontinue taking medicine for at least 48 h prior to sampling collection (11), and one explored the effect of medication by removing 19 medicated cases from a regression model (15). For the use of probiotics, two studies asked participants not to receive any probiotics (12, 16). Other studies did not clearly state the usage of probiotics (10, 11, 13–15, 17).

Another aspect to highlight was the preparation of fecal samples. Most studies sequenced each sample of all participants separately. Nevertheless, Zhou et al. (17) made mixed fecal samples of ADHD patients by taking 1.0 g fecal samples from each ADHD child and dissolving them in 10 ml of sterile distilled water (17).


Assessment of Study Quality

All included studies were assessed for quality using the NOS (**Table 2**). All studies were of high quality and were included in the meta-analysis.

Differences in Diversity Outcomes Between ADHD Patients and HCs Alpha Diversity

Table 3 presents different kinds of alpha diversity indexes used in the included studies to assess the microbial diversity within the same group, including estimated richness (observed OTUs, observed species, Chao1 index), and indexes presented richness and evenness (Shannon index, Simpson index).

For richness, 2 studies (13, 15) provided data on observed OTUs in ADHD patients (n=71) vs HCs (n=78), 2 studies (11, 16) provided observed species in ADHD (n=33) vs HCs (n=94), and 5 studies (10–14) provided Chao1 in ADHD (n=131) vs HCs (n=173). There were no significant differences in SMDs of observed OTUs (SMD = 1.27; 95% CI, -1.21 to 3.75; P = 0.31; $I^2 = 97\%$) (**Figure 2A**), observed species (SMD = 0.02; 95% CI, -0.61 to 0.64; P = 0.96; $I^2 = 52\%$) (**Figure 2B**) or Chao1 (SMD = 0.83; 95% CI, -0.17 to 1.82; P = 0.10; $I^2 = 93\%$) (**Figure 2C**) indexes.



Regarding richness and evenness, 8 studies (10–17) provided data on the Shannon index in ADHD (n=316) vs HCs (n=359), and 5 studies (12–14, 16, 17) provided the Simpson index in ADHD (n=242) vs HCs (n=217). The estimate demonstrated a higher Shannon index in ADHD patients than in HCs (SMD = 0.97; 95% CI, 0.13 to 1.82; P = 0.02; $I^2 = 96\%$) (**Figure 3A**) and no significant difference in the Simpson index (SMD = 0.01; 95% CI, -1.58 to 1.60; P = 0.13; $I^2 = 96\%$) (**Figure 3B**).

In order to explore the high heterogeneity (I^2) of Chao1 index, Shannon index, and Simpson index, we wanted to perform subgroup analyses and meta-regression but gave up because of limited literature. Then, we found that the heterogeneity was skewed by the results from two outlier studies Wang et al. and Zhou et al. (13, 17), and a sensitivity analysis excluded the two studies and produced a homogeneous study population (**Figure 4**). This high heterogeneity could be due to the preparation of fecal samples (17) and pipeline analyses (13) as described in the study characteristics above. However, there were no significant differences between ADHD patients and HCs in any alpha diversity index.

Beta Diversity

Seven studies reported four types of beta diversity, and the findings were inconsistent (**Table 3**); five records showed no significant difference between ADHD patients and HCs, while two reported the opposite conclusion. We did not conduct a meta-analysis on beta diversity because of few data.

TABLE 1 | Characteristics of the studies included in the meta-analysis.

Study	Country		Age	Sex (male	N ^b	Age	Sex	Definition of	Ba	cteria	Microbiology	Dietary	Probiotics
		(ADHD)	(years)	(male, %)	(Control)	(years)	(male, %)	ADHD	Bacteria Identified	Bacteria Altered	Assessment	Assessment	Usage Assessment
Aarts et al. (10)	The Netherlands	19	19.5 (2.5)	68.4%	77	27.1 (14.3) (33 older participants)	53.2%	DSM-IV; Schedule for Affective Disorders and Schizophrenia for School- Age Children	Phylum: Firmicutes, Actinobacteria, Bacteroidetes Order: Clostridiales Family: Rikenellaceae, Porphyromonadaceae Genus: Bifidobacterium, Eggerthella	Phylum: Firmicutes↓, Actinobacteria↑ Genus: Bifidobacterium↑	16S rRNA gene sequencing using 454 pyrosequencing; region: V3-V4; Pipeline analysis: QIIME version 1.2	-	-
Prehn- Kristensen et al. (11)	Germany	14	11.9 (2.5)	14 (100%)	17	13.1 (1.7)	17 (100%)	DSM-IV-TR; K-SADS-PL	Family: Prevotellaceae, Catabacteriaceae, Porphyromonadaceae, Neisseriaceae, Bacteroidaceae Genus: Bacteroides, Prevotella, Parabacteroides, Neisseria	Family: Prevotellaceae↓, Catabacteriaceae↓, Porphyromonadaceae↓, Neisseriaceae↑, Bacteroidaceae↑ Genus: Bacteroides↑, Parabacteroides↓	16S rRNA gene sequencing using Illumina MiSeq; region: V1-V2; Pipeline analysis: Mothur	-	-
Jiang et al. (12)	China	51	8.47 (8.47)	38 (74.51%)	32	8.5 (8.47)	22 (68.75%)	DSM-IV; K-SADS-PL	Phylum: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria Family: Alcaligenaceae, Peptostreptococcaceae, Moraxellaceae, Xanthomonadaceae, Peptococcaceae Genus: Faecalibacterium, Lachnoclostridium, Dialister, Sutterella, Blautia	family: Alcaligenaceae↓, Peptostreptococcaceae↑, Moraxellaceae↑, Xanthomonadaceae↑, Peptococcaceae↑ Genus: Faecalibacterium↓, Lachnoclostridium↓, Dialister↓, Sutterella↓, Blautia↑	16S rRNA gene sequencing using Illumina MiSeq; region: V3-V4; Pipeline analysis: QIIME version 1.7	Yes	No
Wang et al. (13)	Taiwan	30	8.4 (1.7)	23 (76.7%)	30	9.3 (2.2)	18 (60%)	DSM-IV-TR; K-SADS-E	Phylum: Bacteroidetes, Firmicutes, Proteobacteria, Fusobacteria, Actinobacteria Genus: Bacteroidetes, Prevotella, Parabacteroides, Phascolarctobacterium,	Phylum: Fusobacteria↑ Genus: Fusobacteria↑	16S rRNA gene sequencing using Illumina Miseq sequences; region: V3-V4; Pipeline analysis: Mothur and QIIME	Yes	-

(Continued)

Gut Microbiota and ADHD

Study	Country	N ^a (ADHD)	Age (years)	Sex (male,	N ^b (Control)	Age (years)	Sex (male,	Definition of ADHD	Ba	cteria	Microbiology Assessment	Dietary Assessment	Probiotics Usage
				%)			%)		Bacteria Identified	Bacteria Altered			Assessmen
									Escherichia Shigella, Alistipes, Veillonella, Sutterella, Fusobacteria, Akkermansia				
Wan et al. (14)	China	17	8 (7,10)	14 (82.3%)	17	8 (7,9.5)	13 (76.5%)	DSM-V; K-SADS	Arkernansia Genus: Faecalibacterium, Veillonellaceae, Odoribacter, Enterococcus Species: Faecalibacterium prausnitzii, Lachnospiraceae bacterium, Ruminococcus gnavus, Ruminococcaceae, Bacteroides caccae, Odoribacter splanchnicus, Paraprevotella xylaniphila, Veillonella parvula, Odoribacteraceae, Enterococcaceae	Genus: Faecalibacterium↓, Veillonellaceae↓, Odoribacter↑, Enterococcus↑ Species: Faecalibacterium prausnitzii↓, Lachnospiraceae bacterium↓, Ruminococcus gnavus↓, Ruminococcaceae↓, Bacteroides caccae↑, Odoribacter splanchnicus↑, Paraprevotella xylaniphila↑, Veillonella parvula↑, Odoribacteraceae↑, Enterococcaceae↑	Shotgun metagenomics sequencing using Illumina NovaSeq; Platform: Bowtie2	-	-
Szopinska- Tokov et al. (15)	The Netherlands	41	20.2 (4.1)	61%	48	20.4 (3.5)	50%	DSM-IV; K-SADS	Phylum: Clostridiales, Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Verrucomicrobia Genus: Coprococcus_2, Prevotella_9, Intestinibacter	Genus: <i>Coprococcus_</i> 2↓, <i>Prevotella_</i> 9↓	16S rRNA gene sequencing using Illumina Hiseq sequences; region: V1-V2	-	-
Richarte et al. (16)	Spain	100	33 (11)	51%	100	30 (8)	47%	Structured Diagnostic Interview for Adult ADHD (DIVA 2.0), the Structured Clinical Interview for DSM-IV Axis I and II Disorders	Phylum: Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, Verrucomicrobia, Candidatus Melainabacteria Family: Eubacteriaceae, Gracilibacteraceae, Lactobacillaceae, Peptostreptococcaceae, Selenomonadaceae,	Family: Veillonellaceae↑ Genus: Dialister↑	16S rRNA gene sequencing using Illumina Miseq sequences region: V3-V4	-	No

(Continued)

Gut Microbiota and ADHD

TABLE 1 | Continued

Study	Country	N ^a	Age	Sex	N ^b	Age	Sex	Definition of	Ba	cteria	Microbiology	Dietary	Probiotics
		(ADHD)	(years)	(male, %)	(Control)	(years)	(male, %)	ADHD	Bacteria Identified	Bacteria Altered	Assessment	Assessment	Usage Assessment
								(SCID-I and SCID-II)	Veillonellaceae, Verrucomicrobiaceae Genus: Acetivibrio, Alloprevotella, Anaerotaenia, Dialister, Flintibacter, Fucophilus, Gracilibacter, Herbinix, Leclercia, Megamonas, Megasphaera, Odoribacter, Parasutterella, Porphyromonas, Prevotellamassilia, Romboutsia, Vampirovibrio				
Zhou et al. (17)	China	44	6.9	_	38	8.6	-	DSM-V	Genus: Bifidobacterium, Gemmiger Species: Shigella, SMB53, uricibacter, Shigella, Bifidobacterium, Collinsella,Ruminococcus, Clostridium, Roseburia, Gemmiger, Acinetobacter, Enterococcus, Bacteroides, Streptococcus, Faecalibacterium	Genus: Bifidobacterium↓ Species: Shigella↓, SMB53↓, uricibacter↓, Shigella↓, Bifidobacterium↓, Collinsella↓, Ruminococcus↓, Clostridium↓, Roseburia↑, Gemmiger↑, Acinetobacter↑, Enterococcus↑, Bacteroides↑, Streptococcus↑, Faecallbacterium↑	16S rRNA gene sequencing using Illumina Miseq sequences; region: V3-V4; Pipeline analysis: QIIME2 version 2020.06	-	-

^aThe number of ADHD patients in each study; ^bThe number of healthy controls in each study ↑: indicating the increase of bacterial taxa; ↓: indicating the decrease of bacterial taxa. Wang et al.

TABLE 2 | Newcastle–Ottawa Scale for assessing the quality of the studies included in the meta-analysis.

Author, year	Overall		Selection			Comparability		Exposure	
	score	Definition adequate	Representativeness of the cases	Selection of controls	Definition of controls	Comparability of cases and controls	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non- Response rate
Aarts et al., 2017 (10)	8	1	1	1	1	2	0	1	1
Prehn- Kristensen et al., 2018 (11)	9	1	1	1	1	2	1	1	1
Jiang et al., 2018 (12)	9	1	1	1	1	2	1	1	1
Wang et al., 2020	9	1	1	1	1	2	1	1	1
Wan et al., 2020 (14)	9	1	1	1	1	2	1	1	1
Szopinska- Tokov et al., 2020 (15)	9	1	1	1	1	2	1	1	1
Richarte et al., 2021 (16)	9	1	1	1	1	2	1	1	1
Zhou et al., 2021 (17)	8	1	1	1	1	2	0	1	1

TABLE 3 | Summary of diversity assessments in the included studies.

Study	α -diversity	Findings	β -diversity	Findings
Szopinska-Tokov et al. (15)	Observed OTUs Shannon index Phylogenetic index	no difference	weighted UniFrac distances	no difference
Prehn-Kristensen et al. (11)	Observed species Shannon diversity Chao1 index	The ADHD group had lower Shannon diversity than HCs.	Bray–Curtis distance	a significant difference
Wan et al. (14)	Shannon index Chao1 index Simpson index	no difference	-	-
Wang et al. (2020)	Chao1 index Observed OTUs Shannon index	The ADHD group had higher Shannon index and Chao index than HCs. However, the Simpson index was lower in ADHD group.	unweighted and weighted unifrac distances	no difference
Aarts et al. (10)	PD whole tree Chao1 index Observed Species Shannon index	no difference	weighted UniFrac distances	no difference
Jiang et al. (12)	Shannon index Simpson	no difference	unweighted and weighted UniFrac distances, Bray–Curtis distance	no difference

TABLE 3 | Continued

Study	α -diversity	Findings	β-diversity	Findings
	index			
	ACE			
	Chao1 index			
Richarte et al.	Simpson	no difference	unweighted and weighted	no difference
(16)	index		UniFrac distances,	
	Shannon		Bray-Curtis distance	
	index			
Zhou et al. (17)	Shannon	The ADHD group had higher indexes than HCs.	weighted UniFrac	a significant
	index		unweighted UniFrac	difference
	Simpson		Jaccard distance	
	index		Bray–Curtis distance	
	Pielou's		.,	
	evenness			


Differences in Microbial Taxa Between ADHD Patients and HCs

Bacterial Phylum

At the phylum level, five phyla were identified: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia (**Figure 5**). There were no significant differences in phylum.

Because of the high heterogeneity (I^2) of Firmicutes and Actinobacteria, sensitivity analyses excluded the study of Zhou et al. (17) because of the same reason above, and the model was

A Observed OTUs



B Observed Species

	A	ADHD		Health	ny Contr	ol	1	Std. Mean Difference		Std.	Mean Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C		IV,	Random, 95	% CI	
Aart 2017	182.49	56.85	19	196.94	55.75	77	58.0%	-0.26 [-0.76, 0.25]					
Prehn-Kristensen 2018	1,987.56	340.62	14	1,813.35	497.99	17	42.0%	0.39 [-0.32, 1.11]					
Total (95% CI)			33			94	100.0%	0.02 [-0.61, 0.64]			+		
Heterogeneity: Tau ² = 0.	11; Chi ² = 2	2.10, df =	1 (P =	0.15); l ² =	52%				-10	-5	0	5	10
Test for overall effect: Z	= 0.05 (P =	0.96)							-10	Favours (A	DHD1 Favor	urs [control]	

C Chao1 Index

	1	ADHD		Healt	hy Control	1		Std. Mean Difference		Std.	Mean Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C		IV.	Random, 95%	CI	
Aart 2017	579.68	244.29	19	604.82	236.57	77	20.6%	-0.10 [-0.61, 0.40]			+		
Jiang 2018	246.12	58.39	51	229.97	54.49	32	20.9%	0.28 [-0.16, 0.73]			-		
Prehn-Kristensen 2018	12,055.98	3,294.96	14	10,625.35	3,493.93	17	19.6%	0.41 [-0.31, 1.12]					
Wan 2020	61.5	11.6	17	57.5	9.8	17	19.8%	0.36 [-0.31, 1.04]			-		
Wang 2020	2,789	212	30	2,144	168.1	30	19.1%	3.33 [2.53, 4.12]					
Total (95% CI)			131			173	100.0%	0.83 [-0.17, 1.82]			•		
Heterogeneity: Tau ² = 1.1	19; Chi² = 54	.99, df = 4	(P < 0.0	00001); l ² =	93%				-10	6	0	5	10
Test for overall effect: Z =	= 1.62 (P = 0	.10)							-10	-5 Favours (A	DHDI] Favou	rs [control]	10

FIGURE 2 | Forest Plots of Alpha Diversity Richness Estimators in the Gut Microbiota of ADHD Compared with HCs. (A) Observed OTUs; (B) Observed Species; (C) Chao1 index. Cl, confidence interval; SMD, standardized mean difference.

A Shannon Index




FIGURE 3 | Forest Plots of Alpha Diversity richness and evenness in the Gut Microbiota of ADHD Compared with HCs. (A) Shannon index; (B) Simpson index. CI, confidence interval; SMD, standardized mean difference.

switched from a random-effects to a fixed-effects model, with a modest impact on the result (**Figure 6**).

Bacterial Family

At the family level, eight families were identified: Alcaligenaceae, Peptostreptococcaceae, Porphyromonadaceae, Veillonellaceae, Rikenellaceae, Lachnospiraceae, Ruminococcaceae and Bacteroidaceae (**Figure 7**). No significant difference was found in family.

Bacterial Genus

Figure 8 shows the fourteen genera that were identified: *Prevotella_9* (12, 15), *Coprococcus_2* (11, 15), *Parabacteroides* (11, 13), *Phascolarctobacterium* (12, 13), *Escherichia Shigella* (12, 13), *Alistipes* (11–13), *Sutteralla* (11, 13), *Veillonella* (13, 14), *Odoribacter* (14, 16), *Faecalibacterium* (11, 12, 14, 17), *Bacteroides* (12, 13), *Bifidobacterium* (12, 17), *Dialister* (11, 12, 16) and *Blautia* (11, 12, 17).

Sensitivity analyses were conducted because of the high heterogeneity of *Alistipes, Faecalibacterium* and *Dialister*, and the model was changed from a random-effects to a fixed-effects model, with a similar result described above (**Figure 9**).

As shown in the forest plot (**Figure 9**), the relative abundance of *Blautia* was significantly higher in ADHD patients than in HCs (SMD = 0.34; 95% CI, 0.06 to 0.63; P = 0.02; $I^2 = 0\%$). For other genera, no significant difference was found.

Table 4 summarizes the outcomes of the included studies on microbiota profiles (alpha and beta diversity) and gut microbiota

taxa. Different studies did not draw consistent conclusions. For α -diversity, five studies reported nonsignificant differences, but Prehn-Kristensen et al. (11), Wang et al. (13, 18), and Zhou et al. (17) gave different outcomes. Wang et al. (13, 18) and Zhou et al. (17) found a higher Shannon index, but they reached contradictory conclusions on the Simpson index, which may be led by different pipeline analyses of Mothur and QIIME. Prehn-Kristensen et al. (11) disagreed because he found a decrease in the Shannon index. Seven studies addressed β -diversity, with two believed significant differences in all four indexes, while others derived opposite findings. Regarding gut microbiota taxa, different researchers reached different or even contrary conclusions, as shown in **Table 4**.

Publication Bias

Potential publication biases were observed in funnel plots of Chao1 index and Shannon index which were presented in **Supplementary Material 3**. Egger's test further confirmed the significant bias in Shannon index (P = 0.050), but not in Chao1 index (P = 0.218).

DISCUSSION

To our knowledge, this is the first meta-analysis to identify evidence on the dysbiosis of gut microbiota in ADHD. We searched five important databases to accumulate evidence on whether ADHD patients have a different gut microbial

Chao1 Index Δ ADHD Healthy Control Std. Mean Difference Std. Mean Difference Study or Subgroup SD Total Mean Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI 579.68 244.29 Aart 2017 19 604.82 236.57 77 30.1% -0.10 [-0.61, 0.40] 0.28 [-0.16. 0.73] Jiang 2018 246 12 58.39 51 229 97 5/ /0 32 38.5% Prehn-Kristensen 2018 12.055.98 3.294.96 14 10 625 35 3 493 93 17 14.8% 0 41 [-0 31 1 12] 17 17 Wan 2020 615 116 57.5 98 16.5% 0.36 [-0.31 1.04] Wang 2020 2.789 212 30 2,144 168.1 30 0.0% 3.33 [2.53, 4.12] Total (95% CI) 101 143 100.0% 0.20 [-0.08, 0.47] Heterogeneity: Chi² = 2.09, df = 3 (P = 0.55); I² = 0% -10 10 -5 Test for overall effect: Z = 1.40 (P = 0.16) Favours [ADHDI] Favours [control] R Shannon Index ADHD Healthy Control Std. Mean Difference Std. Mean Difference Study or Subgro SD Total Mean SD Total Weight IV, Random, 95% Cl IV, Random, 95% CI Aart 2017 5.32 0.97 19 5.19 0.76 77 12.4% 0.16 [-0.34, 0.66] Jiang 2018 Prehn-Krist 0.97 0.44 2.24 0.4 0.41 51 14 100 0.4 0.4 0.35 3.36 32 17 16.0% 0.05 [-0.40, 0.49] 3.34 5.58 2.93 6.2% 40.7% 5.89 0.20 [-0.51, 0.91 2018 Richarte 2021 100 -0.05 [-0.33, 0.22] 2.91 Szopinska-Tokov 2020 3.87 41 17 3.89 0.34 48 17 18.0% -0.05 [-0.47, 0.36] Wan 2020 9.67 0.42 9.52 0.25 6.7% 0 42 [-0 26, 1, 10] 0.08 Wang 2020 Zhou 2021 2 92 30 44 2.65 0.08 30 38 0.0% 3 33 12 53 4 13 4.07 [3.30, 4.84] 6.67 Total (95% CI) 0.04 [-0.14, 0.21] 291 Heterogeneity: Tau² = 0.00; Chi² = 2.25, df = 5 (P = 0.81); l² = 0% -10 10 -5 5 -5 U S Favours [ADHD] Favours [control] Test for overall effect: 7 = 0.41 (P = 0.68) С Simpson Index Std. Mean Difference Std. Mean Differenc ADHD Healthy Control Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI IV. Random, 95% CI 0.08 0.04 0.08 0.04 0.00 [-0.44, 0.44] Jiang 2018 51 32 25.2% -0.16 [-0.44, 0.11 Richarte 2021 0.87 0.07 63.9% 100 0.88 0.05 100 Wan 2020 0.89 0.07 17 0.88 0.06 17 10.9% 0.15 [-0.52, 0.82] Wang 2020 0.13 0.01 30 0.17 0.01 30 0.0% -3.95 [-4.84, -3.06 Zhou 2021 0.95 0.01 44 0.91 0.01 38 0.0% 3.96 [3.20, 4.72] Total (95% CI) 149 100.0% 168 -0.09 [-0.31, 0.13] Heterogeneity: Tau² = 0.00; Chi² = 0.92, df = 2 (P = 0.63); I² = 0% -10 -5 10 0 Test for overall effect: Z = 0.78 (P = 0.44) Favours [ADHD] Favours [control] FIGURE 4 | Sensitivity analysis of alpha diversity in the gut microbiota of ADHD compared with HCs after removing heterogeneous studies of Wang 2020 and Zhou 2021 (17). (A) Chao1 index; (B) Shannon index; (C) Simpson index. Cl, confidence interval; SMD, standardized mean difference

composition than healthy controls. A total of eight studies with high quality were included, including 316 ADHD patients and 359 healthy controls. Then, we investigated the diversity and relative abundance of the gut microbiota, more specifically at the 5 phyla, 8 families and 14 genera. Our findings are as follows. First, for the alpha diversity of ADHD patients and HCs, we only found a higher Shannon index in ADHD, but the significance vanished after sensitivity analysis because of high heterogeneity. Second, at the phylum level, no significant difference was found. And at the family level, there was no difference between ADHD and HCs. Finally, at the genus level, *Blautia* was significantly elevated in ADHD patients.

It is worth noting that several systematic reviews (7, 19, 20) summarized differences in gut microbiota between the ADHD group and healthy group but did not draw a final conclusion. They led to a conflicting or even opposite conclusion.

Regarding the alpha diversity of gut microbiota, we found that the Shannon index, which provides information on richness and evenness of gut microbiota, was elevated in ADHD patients, which meant that the within-group diversity was higher in the ADHD group. The result of Shannon index was consistent with reports drawn by Wang et al. (13, 18) and Zhou et al. (17), but we found the heterogeneity was high, and coincidentally, the two studies of Wang et al. (13, 18) and Zhou et al. (17) contributed to it. The possible reasons for this might be the difference in the fecal sampling method of Zhou et al. (17) and pipeline analyses of Wang et al. (13, 18). After sensitivity analysis which excluded the two outlier studies, the difference of Shannon index disappeared. For beta diversity, we did not conduct a meta-analysis due to the inadequate number of studies with available data. Therefore, further studies are needed to explore the association between the diversity of gut microbiota and ADHD.

For specific gut microbiota taxa, we selected bacteria that had two or more studies with sufficient data in the meta-analysis. Our findings that there were no significant differences in bacterial phyla and families were not entirely in tune with previous studies (7, 20). Some studies reported an increased or decreased level of phyla or families, but most studies were in agreement with our study. For the bacterial genus, we found that *Blautia* was significantly higher in ADHD patients, which may serve as a

Study or Subgroup	Mean		Total	C Mean	ontrol:	Total	S Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
2.1.1 Firmicutes	Weall	30	TOLAI	Weall	30	TOLAI	weight	IV, Kaliuolii, 95 /6 Ci	
Jiang 2018	0.5	15.89	51	0.47	15.32	32	4.0%	0.001.0.44.0.441	+
Prehn-Kristensen 2018			51	13.66	0.32			0.00 [-0.44, 0.44]	
	13.51	0.61				17	3.4%	-0.31 [-1.02, 0.40]	Ļ
Richarte 2021	0.42	8.2	100	0.42	8.3	100	4.2%	0.00 [-0.28, 0.28]	L
Szopinska-Tokov 2020	76.48	14.9		75.14		48	4.0%	0.08 [-0.34, 0.50]	
Wang 2020	10.57	3.75		12.01	6.34	30	3.8%	-0.27 [-0.78, 0.24]	
Zhou 2021 Subtotal (95% CI)	55.73	3.6	280	41.34	1.19	38 265	3.0% 22.4%	5.16 [4.24, 6.08] 0.70 [-0.24, 1.65]	
Heterogeneity: $Tau^2 = 1$.	01. Chi2.	- 100 0			00004)			0.70 [-0.24, 1.05]	•
Test for overall effect: Z				5 (F < 0	.00001)	, 1 90	J 70		
2.1.2 Bacteroidetes									
Jiang 2018	0.38	19.57	51	0.41	18.72	32	4.0%	-0.00 [-0.44, 0.44]	+
Prehn-Kristensen 2018	12.65	0.92	14	12.61	0.37	17	3.4%	0.06 [-0.65, 0.77]	+
Richarte 2021	0.49	8.7	100	0.48	9.2	100	4.2%	0.00 [-0.28, 0.28]	†
Szopinska-Tokov 2020	20.28	17.66	41	21.27	21.72	48	4.0%	-0.05 [-0.47, 0.37]	+
Wang 2020	70.64	10.21	30	74.07	9.98	30	3.8%	-0.34 [-0.85, 0.17]	-+
Zhou 2021	0.6	0.31	44	0.58	0.12	38	4.0%	0.08 [-0.35, 0.52]	t
Subtotal (95% CI)			280			265	23.4%	-0.03 [-0.20, 0.14]	1
Heterogeneity: Tau ² = 0. Test for overall effect: Z			```	P = 0.88	3); I² = 0	%			
2.1.3 Actinobacteria									
Jiang 2018	0.05	6.46	51	0.03	4.27	32	4.0%	0.00 [-0.44, 0.45]	+
Prehn-Kristensen 2018	4.35	2.92	14	5.46	2.22	17	3.4%	-0.42 [-1.14, 0.29]	
Richarte 2021	1.3	1.7	100	1.4	1.6	100	4.2%	-0.06 [-0.34, 0.22]	t
Szopinska-Tokov 2020	1.17	1.7	41	0.72	1.04	48	4.0%	0.32 [-0.10, 0.74]	+
Wang 2020	1	1.7	30	0.51	0.89	30	3.8%	0.36 [-0.15, 0.87]	<u>+</u> -
Zhou 2021	40.11	4.02	44	55.11	1.36	38	3.1%	-4.81 [-5.68, -3.94]	
Subtotal (95% CI)			280			265	22.5%	-0.70 [-1.65, 0.24]	•
Heterogeneity: Tau ² = 1. Test for overall effect: Z				5 (P < 0	.00001)	; I² = 96	5%		
2.1.4 Proteobacteria									
Jiang 2018	0.06		51	8.37	6.63	32	3.9%	-1.04 [-1.51, -0.57]	
Prehn-Kristensen 2018	8.25	1.91	14	8.36	1.18	17	3.4%	-0.07 [-0.78, 0.64]	Ţ
Richarte 2021	0.06	3.8	100	0.06	3.7	100	4.2%	0.00 [-0.28, 0.28]	1
Szopinska-Tokov 2020	0.21	0.37	41	0.29	0.48	48	4.0%	-0.18 [-0.60, 0.23]	1
Wang 2020	9.39	6.52	30	8.46	4.76	30	3.8%	0.16 [-0.35, 0.67]	Ĺ.
Zhou 2021	3.26	1.18	44	2.86	0.33	38	4.0%	0.44 [0.00, 0.88]	↓ [−]
Subtotal (95% Cl)	17. 01:2	- 00 75	280 df = 5	(D - 0 (10041-12	265	23.4%	-0.11 [-0.50, 0.27]	Ţ
Heterogeneity: Tau ² = 0. Test for overall effect: Z	,		,	(P = 0.0	JUU4); I ²	- 78%			
2.1.5 Verrucomicrobia									
Richarte 2021	1.3		100	1.3	2.5	100	4.2%	0.00 [-0.28, 0.28]	†
Szopinska-Tokov 2020	0.12	0.26	41	0.2	0.34	48	4.0%	-0.26 [-0.68, 0.16]	7
Subtotal (95% CI) Heterogeneity: Tau ² = 0.	00; Chi²	= 1.02,	141 df = 1 (i	P = 0.3'	1); l² = 2	148 %	8.2%	-0.08 [-0.32, 0.15]	•
Test for overall effect: Z									
Total (95% CI) Heterogeneity: Tau ² = 0.	16. Chi2	- 070 -	1261	25 (P -	0 00004		100.0%	-0.05 [-0.33, 0.23] 	· · · · · · · · · · · · · · · · · · ·
Test for overall effect: Z					0.0000	·,, · - :	. /0	-1	
	,		, ,	1 (P = 0	34) 12 -	- 11 0%	ć		Favours [ADHD] Favours [control]
Test for subaroup differe	nces: Cn	1 - 4.0	0. ui - •	+11 - 0	.041.1 -	- 11.07	0		

		ADHD	T (1)		Control	T (1)		td. Mean Difference	Std. Mean Difference
Study or Subgroup 2.1.1 Firmicutes	Mean	SD	lotal	Mean	SD	lotal	Weight	IV, Fixed, 95% C	IV, Fixed, 95% Cl
Jiang 2018	0.5	15 00	51	0 47	15 22	22	2 60/	144.0.44.0.100.0	Ļ
0		15.89	51		15.32	32	3.6%	0.00 [-0.44, 0.44]	
Prehn-Kristensen 2018	13.51	0.61		13.66	0.32	17	1.4%	-0.31 [-1.02, 0.40]	
Richarte 2021	0.42	8.2		0.42	8.3	100	9.1%	0.00 [-0.28, 0.28]	I
Szopinska-Tokov 2020	76.48	14.9		75.14		48	4.0%	0.08 [-0.34, 0.50]	
Wang 2020	10.57	3.75		12.01	6.34	30	2.7%	-0.27 [-0.78, 0.24]	
Zhou 2021	55.73	3.6		41.34	1.19	38	0.0%	5.16 [4.24, 6.08]	
Subtotal (95% CI)			236			227	20.8%	-0.04 [-0.22, 0.14]	
Heterogeneity: Chi ² = 1.7	78, df = 4	(P = 0.	.78); l² :	= 0%					
Test for overall effect: Z	= 0.43 (F	P = 0.67)						
2.1.2 Bacteroidetes									
Jiang 2018	0.38	19.57	51	0.41	18.72	32	3.6%	-0.00 [-0.44, 0.44]	+
Prehn-Kristensen 2018	12.65	0.92		12.61		17	1.4%	0.06 [-0.65, 0.77]	+
Richarte 2021	0.49	8.7		0.48	9.2	100	9.1%	0.00 [-0.03, 0.77]	+
Szopinska-Tokov 2020		17.66		21.27		48	4.0%	-0.05 [-0.47, 0.37]	+
Wang 2020	20.20 70.64			74.07	9.98	40 30	4.0% 2.7%	• • •	4
	70.64 0.6		30 44	0.58	9.98	30 38		-0.34 [-0.85, 0.17]	Ļ
Zhou 2021 Subtotal (95% CI)	0.0	0.31	44 280	0.00	U. 12	38 265	3.7% 24.5%	0.08 [-0.35, 0.52] -0.03 [-0.20, 0.14]	
, ,	76 44 - 5	(D - 0		- 00/		200	27.J/0	-0.00 [-0.20, 0.14]	
Heterogeneity: Chi ² = 1.7 Test for overall effect: Z		•		= 0%					
	0.01 (i	0.71	/						
2.1.3 Actinobacteria									
Jiang 2018		6.46	51	0.03	4.27	32	3.6%	0.00 [-0.44, 0.45]	Ť
Prehn-Kristensen 2018	4.35	2.92	14	5.46	2.22	17	1.4%	-0.42 [-1.14, 0.29]	
Richarte 2021	1.3	1.7	100	1.4	1.6	100	9.1%	-0.06 [-0.34, 0.22]	t
Szopinska-Tokov 2020	1.17	1.7	41	0.72	1.04	48	4.0%	0.32 [-0.10, 0.74]	
Wang 2020	1	1.7	30	0.51	0.89	30	2.7%	0.36 [-0.15, 0.87]	<u>+</u>
Zhou 2021	40.11	4.02	44	55.11	1.36	38	0.0%	-4.81 [-5.68, -3.94]	
Subtotal (95% CI)			236			227	20.7%	0.05 [-0.13, 0.24]	•
Heterogeneity: Chi ² = 5.3		•		= 25%					
Test for overall effect: Z	= 0.58 (F	° = 0.56)						
2.1.4 Proteobacteria									
Jiang 2018	0.06	8.65	51	8.37	6.63	32	0.0%	-1.04 [-1.51, -0.57]	
Prehn-Kristensen 2018	8.25	1.91	14	8.36	1.18	17	1.4%	-0.07 [-0.78, 0.64]	+
Richarte 2021	0.06	3.8	100	0.06	3.7	100	9.1%	0.00 [-0.28, 0.28]	+
Szopinska-Tokov 2020	0.21	0.37	41		0.48	48	4.0%	-0.18 [-0.60, 0.23]	+
Wang 2020	9.39	6.52	30		4.76	30	2.7%	0.16 [-0.35, 0.67]	+
Zhou 2021	3.26	1.18		2.86		38	3.6%	0.44 [0.00, 0.88]	+
Subtotal (95% CI)			229			233	20.9%	0.06 [-0.13, 0.24]	•
Heterogeneity: Chi ² = 4.6	68, df = 4	(P = 0.	.32); ² :	= 15%					
Test for overall effect: Z	= 0.62 (F	P = 0.53)						
2.1.5 Verrucomicrobia									
Richarte 2021	1.3	2 F	100	1 2	2 F	100	Q 1%	0.00 [-0.28, 0.28]	+
Szopinska-Tokov 2020		2.5 0.26	41		2.5 0.34	100 48	9.1% 4.0%		4
Szopińska-Tokov 2020 Subtotal (95% CI)	U. 12	0.20	41 141	0.2	0.34	48 148		-0.26 [-0.68, 0.16] -0.08 [-0.31, 0.15]	4
	00 df - 4	(D – O		- 20/		140	10.170	-0.00 [-0.31, 0.15]	1
Heterogeneity: Chi ² = 1.0 Test for overall effect: Z				- 270					
	5.51 (I	0.00	,						
			1122			1100	100.0%	-0.00 [-0.09, 0.08]	
Total (95% CI)									
Total (95% CI) Heterogeneity: Chi ² = 16	i.05, df =	22 (P =	: 0.81);	l² = 0%					-10 -5 0 5 10

FIGURE 6 | Sensitivity analysis after removing heterogeneous studies of relative abundance of Phylum in the Gut Microbiota of ADHD Compared with HCs. Cl, confidence interval; SMD, standardized mean difference.

Chudu an Culture		ADHD	Ta4-1		ontrol	T.4-1		td. Mean Difference	Std. Mean Difference
Study or Subgroup 3.1.1 Alcaligenaceae	Mean	SD	Total	wean	SD	iotal	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
Jiang 2018	0.02	2.8	51	0.03	2.59	32	6.4%	-0.00 [-0.45, 0.44]	+
Prehn-Kristensen 2018		1.94	14		1.33	17	2.5%	0.24 [-0.47, 0.96]	+-
Subtotal (95% CI)			65			49	8.8%	0.07 [-0.31, 0.44]	◆
Heterogeneity: Chi ² = 0.3		•		:0%					
Test for overall effect: Z	= 0.34 (P	= 0.73)						
3.1.2 Peptostreptococo	aceae								
Jiang 2018	0.01	1.67	51	0	0.63	32	6.4%	0.01 [-0.43, 0.45]	Ť
Richarte 2021	0.327	0.55		0.199	0.23	100	16.0%	0.30 [0.02, 0.58]	
Subtotal (95% CI)			151			132	22.3%	0.22 [-0.02, 0.45]	
Heterogeneity: Chi ² = 1.2 Test for overall effect: Z		•		18%					
3.1.3 Porphyromonada	ceae								
Jiang 2018	0.03	2.7	51	0.04	5.18	32	6.4%	-0.00 [-0.44, 0.44]	+
Prehn-Kristensen 2018	5.62		14	7.28	0.97	17	2.3%	-0.82 [-1.56, -0.08]	-
Subtotal (95% CI)			65			49	8.6%	-0.22 [-0.60, 0.16]	♦
Heterogeneity: Chi ² = 3.4	l5, df = 1	(P = 0.	06); l² =	71%				- • •	
Test for overall effect: Z									
3.1.4 Veillonellaceae									
Jiang 2018	0.04	6.48	51	0.06	6.04	32	6.4%	-0.00 [-0.45, 0.44]	+
Prehn-Kristensen 2018		1.71	14	8.1	1.13	17	2.5%	-0.18 [-0.89, 0.53]	1
Richarte 2021	0.02	1.9	100	0.01	1.43	100	16.2%	0.01 [-0.27, 0.28]	I
Subtotal (95% CI)		<i>(</i> D 0 0	165			149	25.0%	-0.01 [-0.24, 0.21]	
Heterogeneity: Chi ² = 0.2 Test for overall effect: Z				: 0%					
3.1.5 Rikenellaceae									
Jiang 2018	0.05	5.94	51	0.06	8.31	32	6.4%	-0.00 [-0.44, 0.44]	+
Prehn-Kristensen 2018	6	2.5	14	7.04	1.7	17	2.4%	-0.48 [-1.20, 0.24]	
Subtotal (95% CI)	· ·	2.0	65			49	8.8%	-0.13 [-0.51, 0.24]	♦
Heterogeneity: Chi ² = 1.2	25, df = 1	(P = 0.	26); l² =	20%					
Test for overall effect: Z									
3.1.6 Lachnospiraceae									
Jiang 2018	0.18	11.02	51	0.15	7.54	32	6.4%	0.00 [-0.44, 0.45]	Ť
Prehn-Kristensen 2018	11.54	0.87	14	11.52	0.78	17	2.5%	0.02 [-0.68, 0.73]	Ť
Subtotal (95% CI)			65			49	8.8%	0.01 [-0.37, 0.38]	₽
Heterogeneity: Chi ² = 0.0 Test for overall effect: Z		`	<i>,.</i>	:0%					
rescior overall effect. Z	- 0.00 (P	- 0.90	,						
3.1.7 Ruminococcacea		0.07		0.00	0.00		0.401	0.001.0.11.0.17	\downarrow
Jiang 2018		9.35		0.22		32	6.4%	-0.00 [-0.44, 0.44]	\bot
Prehn-Kristensen 2018	12.06	0.61		12.16	0.6	17 40	2.5%	-0.16 [-0.87, 0.55]	1
Subtotal (95% CI)	1 44 - 4	(D – C	65 71): 12 -	00/		49	8.8%	-0.05 [-0.42, 0.33]	Ţ
Heterogeneity: Chi ² = 0. Test for overall effect: Z				U%					
3.1.8 Bacteroidaceae									
Jiang 2018	0.27	17 / 2	51	0.29	16 77	32	6.4%	-0.00 [-0.44, 0.44]	Ļ
Prehn-Kristensen 2018	11.92			0.29 11.64		32 17	2.4%	0.31 [-0.44, 0.44]	<u>+-</u>
Subtotal (95% CI)	11.32	1.1	65	11.04	0.02	49	2.4 % 8.8%	0.09 [-0.29, 0.46]	•
Heterogeneity: Chi ² = 0.8		•	46); l² =	:0%				·····	
Test for overall effect: Z	= 0.45 (P	= 0.65)						
Total (95% CI)			706			575	100.0%	0.02 [-0.09, 0.14]	
Heterogeneity: Chi ² = 12	.43, df =	16 (P =	0.71);	² = 0%				F	10 -5 0 5
									10 -5 0 5

FIGURE 7 | Forest plot of relative abundance of Family in the Gut Microbiota of ADHD Compared with HCs. CI, confidence interval; SMD, standardized mean difference.

Study or Subgroup	ADHD Mean SD Tota	Mean SD Tota	al Weight	IV, Random, 95% CI	IV, Random, 95% Cl
4.1.1 Prevotella_9 Jiang 2018 Szopinska-Tokov 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z		1 2.67 5.3 4 2 8	8 3.2%	0.00 [-0.44, 0.44] -0.58 [-1.00, -0.15] -0.29 [-0.86, 0.28]	~
4.1.2 Coprococcus_2 Prehn-Kristensen 2018 Szopinska-Tokov 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z		1 0.75 0.63 4 5 6	8 3.2%	-0.28 [-0.99, 0.43] -1.37 [-1.84, -0.91] -0.86 [-1.93, 0.20]	
4.1.3 Parabacteroides Prehn-Kristensen 2018 Wang 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = 0. Test for overall effect: Z	3.35 2.24 30 44 20; Chi ² = 2.85, df = 1	4 4	0 3.1%	-0.99 [-1.75, -0.24] -0.21 [-0.72, 0.30] -0.55 [-1.31, 0.21]	
4.1.4 Phascolarctobact Jiang 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z	4.68 4.75 51 2.07 2.85 30 81 13; Chi ² = 3.13, df = 1	0 2.56 3.28 3 I 6	0 3.1%	0.45 [0.01, 0.90] -0.16 [-0.66, 0.35] 0.16 [-0.44, 0.76]	
4.1.5 Escherichia Shige Jiang 2018 Wang 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = 0. Test for overall effect: Z	0.02 4.86 51 2.1 3.99 30 81 00; Chi ² = 0.06, df = 1	6	0 3.1%	-0.00 [-0.45, 0.44] 0.08 [-0.42, 0.59] 0.03 [-0.30, 0.37]	•
4.1.6 Alistipes Jiang 2018 Prehn-Kristensen 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z		4 7.5 1.64 1 0 1.16 1.77 3 5 7	7 2.7% 0 3.1%	0.00 [-0.44, 0.44] -0.62 [-1.35, 0.11] 0.63 [0.11, 1.15] 0.04 [-0.59, 0.68]	
4.1.7 Sutterella Prehn-Kristensen 2018 Wang 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = 0. Test for overall effect: Z		0 1.47 3.04 3	0 3.1%	0.19 [-0.52, 0.90] -0.07 [-0.58, 0.44] 0.02 [-0.39, 0.43]	•
4.1.8 Veillonella Wan 2020 Wang 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = 0. Test for overall effect: Z		0 0.79 1.39 3 7 4	0 3.1%	-1.03 [-1.75, -0.31] 0.07 [-0.43, 0.58] -0.45 [-1.52, 0.63]	-
4.1.9 Odoribacter Richarte 2021 Wan 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z		7 1.78 2.11 1 7 11	7 2.8%	-0.31 [-0.59, -0.04] 0.37 [-0.31, 1.04] -0.05 [-0.70, 0.60]	
4.1.10 Faecalibacterium Jiang 2018 Prehn-Kristensen 2018 Wan 2020 Zhou 2021 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Test for overall effect: Z	0.1 6.87 51 9.57 2.19 14 18.69 25.91 17 4.69 1.13 44 126 40; Chi ² = 50.05, df =	4 9.71 0.77 1 7 13.33 17.82 1 4 2.5 0.51 3 5 10	7 2.8% 7 2.8% 8 3.0% 4 11.8%	-0.00 [-0.45, 0.44] -0.09 [-0.79, 0.62] 0.24 [-0.44, 0.91] 2.42 [1.84, 2.99] 0.64 [-0.56, 1.84]	
4.1.11 Bacteroides Jiang 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z	58.38 15.02 30 81 00; Chi² = 0.06, df = 1	6	0 3.1%	-0.00 [-0.44, 0.44] -0.08 [-0.59, 0.42] -0.04 [-0.37, 0.30]	•
4.1.12 Bifidobacterium Jiang 2018 Zhou 2021 Subtotal (95% CI) Heterogeneity: Tau ² = 10 Test for overall effect: Z	95 .32; Chi² = 89.44, df =	4 51.36 1.22 3 5 7	8 2.6% 0 5.8%	0.00 [-0.44, 0.45] -4.56 [-5.40, -3.73] -2.26 [-6.74, 2.21]	
4.1.13 Dialister Jiang 2018 Prehn-Kristensen 2018 Richarte 2021 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z	0.01 2.69 51 7.7 1.68 14 1.38 1.76 100 165 08; Chi ² = 4.95, df = 2 = 0.85 (P = 0.39)	4 7.94 1.13 1 0 0.65 1.26 10 5 14	7 2.8% 0 3.4%	-0.00 [-0.44, 0.44] -0.17 [-0.88, 0.54] 0.48 [0.19, 0.76] 0.18 [-0.23, 0.58]	
4.1.14 Blautia Jiang 2018 Prehn-Kristensen 2018 Zhou 2021 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z		4 5.93 1.49 1 4 8.85 1.32 3 9 8	7 2.8% 8 3.2%	0.56 [0.11, 1.01] -0.01 [-0.71, 0.70] 0.27 [-0.16, 0.71] 0.34 [0.06, 0.63]	
Total (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z Test for subaroup differe	1232 48; Chi² = 276.06, df = = 0.90 (P = 0.37)	= 32 (P < 0.00001); l ²		-0.12 [-0.37, 0.14]	-5 0 5 10 Favours [ADHD] Favours [control]

FIGURE 8 | Forest plot of relative abundance of Genus in the Gut Microbiota of ADHD Compared with HCs. CI, confidence interval; SMD, standardized mean difference.

	ADHD C	ontrol	St	d. Mean Difference	Std. Mean Difference
<u>Study or Subgroup</u> 4.1.1 Prevotella_9 Jiang 2018 Szopinska-Tokov 2020	Mean SD Total Mean 0.03 8.98 51 0.02 0.38 0.7 41 2.67	SD Total 8.03 32 5.3 48	Weight 4.3% 4.6%	IV, Fixed, 95% Cl 0.00 [-0.44, 0.44] -0.58 [-1.00, -0.15]	IV. Fixed by Cl
Test for overall effect: Z =	92 3, df = 1 (P = 0.06); l² = 71% 1.91 (P = 0.06)	80	9.0%	-0.30 [-0.61, 0.01]	•
4.1.2 Coprococcus_2 Prehn-Kristensen 2018 Szopinska-Tokov 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 6.3 Test for overall effect: Z =	6.38 1.7 14 6.78 0.09 0.17 41 0.75 55 2, df = 1 (P = 0.01); I ² = 84% 5.26 (P < 0.00001)	1.06 17 0.63 48 65	3.9%	-0.28 [-0.99, 0.43] -1.37 [-1.84, -0.91] -1.04 [-1.43, -0.66]	•
4.1.3 Parabacteroides Prehn-Kristensen 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 2.8 Test for overall effect: Z =	5.33 2.21 14 7.08 3.35 2.24 30 4.02 44 5, df = 1 (P = 0.09); I ² = 65% 2.11 (P = 0.03)	1.17 17 3.86 30 47	3.3%	-0.99 [-1.75, -0.24] -0.21 [-0.72, 0.30] -0.45 [-0.87, -0.03]	•
4.1.4 Phascolarctobacte Jiang 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 3.1 Test for overall effect: Z =	4.68 4.75 51 2.78 2.07 2.85 30 2.56 81 3, df = 1 (P = 0.08); I ² = 68%	2.96 32 3.28 30 62	3.3%	0.45 [0.01, 0.90] -0.16 [-0.66, 0.35] 0.19 [-0.15, 0.52]	
4.1.5 Escherichia Shige Jiang 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 0.0 Test for overall effect: Z =	0.02 4.86 51 0.04 2.1 3.99 30 1.83 81 6, df = 1 (P = 0.81); I ² = 0%	8.45 32 2.35 30 62	3.3%	-0.00 [-0.45, 0.44] 0.08 [-0.42, 0.59] 0.03 [-0.30, 0.37]	- -
4.1.6 Alistipes Jiang 2018 Prehn-Kristensen 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 2.0 Test for overall effect: Z =	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	6.13 32 1.64 17 1.77 30 49	1.6% 0.0%	0.00 [-0.44, 0.44] -0.62 [-1.35, 0.11] 0.63 [0.11, 1.15] -0.17 [-0.54, 0.21]	
4.1.7 Sutterella Prehn-Kristensen 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 0.3 Test for overall effect: Z =	8.02 2.28 14 7.65 1.27 2.55 30 1.47 44 5, df = 1 (P = 0.55); I ² = 0% 0.09 (P = 0.93)	1.45 17 3.04 30 47	3.3%	0.19 [-0.52, 0.90] -0.07 [-0.58, 0.44] 0.02 [-0.39, 0.43]	-
4.1.8 Veillonella Wan 2020 Wang 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 6.0 Test for overall effect: Z =	$\begin{array}{ccccccc} 0.92 & 0.19 & 17 & 1.27 \\ 0.9 & 1.54 & 30 & 0.79 \\ & 47 \\ 1, df = 1 \; (P = 0.01); \; I^2 = 83\% \\ 1.37 \; (P = 0.17) \end{array}$	0.43 17 1.39 30 47	3.3%	-1.03 [-1.75, -0.31] 0.07 [-0.43, 0.58] -0.29 [-0.70, 0.12]	•
Test for overall effect: Z =	$\begin{array}{ccccccc} 0.55 & 0.34 & 100 & 0.75 \\ 2.65 & 2.52 & 17 & 1.78 \\ & 117 \\ 0, df = 1 (P = 0.07); I^2 = 70\% \\ 1.64 (P = 0.10) \end{array}$	0.83 100 2.11 17 117	1.8%	-0.31 [-0.59, -0.04] 0.37 [-0.31, 1.04] -0.22 [-0.47, 0.04]	-
4.1.10 Faecalibacterium Jiang 2018 Prehn-Kristensen 2018 Wan 2020 Zhou 2021 Subtotal (95% CI) Heterogeneity: Chi ² = 0.4 Test for overall effect: Z =	$\begin{array}{ccccccc} 0.1 & 6.87 & 51 & 0.13\\ 9.57 & 2.19 & 14 & 9.71\\ 18.69 & 25.91 & 17 & 13.33\\ 4.69 & 1.13 & 44 & 2.5\\ 82\\ 3, df=2 \ (P=0.79); \ l^2=0\%\\ 0.21 \ (P=0.84) \end{array}$	0.77 17	1.7% 1.8% 0.0%	-0.00 [-0.45, 0.44] -0.09 [-0.79, 0.62] 0.24 [-0.44, 0.91] 2.42 [1.84, 2.99] 0.03 [-0.29, 0.36]	
4.1.11 Bacteroides Jiang 2018 Wang 2020 Subtotal (95% CI) Heterogeneity: Chi ² = 0.0 Test for overall effect: Z =	0.27 17.54 51 0.29 58.38 15.02 30 59.55 81 5, df = 1 (P = 0.81); I ² = 0% 0.22 (P = 0.83)	16 32 12.08 30 62	3.3%	-0.00 [-0.44, 0.44] -0.08 [-0.59, 0.42] -0.04 [-0.37, 0.30]	÷
4.1.12 Bifidobacterium Jiang 2018 Zhou 2021 Subtotal (95% CI) Heterogeneity: Chi ² = 89. Test for overall effect: Z =	0.04 4.96 51 0.02 37.71 3.88 44 51.36 95 14, df = 1 (P < 0.00001); l ² = 9 4.97 (P < 0.00001)	1.22 38 70	1.2%	0.00 [-0.44, 0.45] -4.56 [-5.40, -3.73] -0.99 [-1.38, -0.60]	- •
4.1.13 Dialister Jiang 2018 Prehn-Kristensen 2018 Richarte 2021 Subtotal (95% CI) Heterogeneity: Chi ² = 0,1 Test for overall effect: Z =	0.01 2.69 51 0.02 7.7 1.68 14 7.94 1.38 1.76 100 0.65 65 5, df = 1 (P = 0.70); I ² = 0% 0.25 (P = 0.80)		1.7% 0.0%	-0.00 [-0.44, 0.44] -0.17 [-0.88, 0.54] 0.48 [0.19, 0.76] -0.05 [-0.42, 0.33]	•
4.1.14 Blautia Jiang 2018 Prehn-Kristensen 2018 Zhou 2021 Subtotal (95% CI) Heterogeneity: Chi ² = 1.9 Test for overall effect: Z =	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1.86 32 1.49 17 1.32 38 87	1.7% 4.4%	0.56 [0.11, 1.01] -0.01 [-0.71, 0.70] 0.27 [-0.16, 0.71] 0.34 [0.06, 0.63]	
Test for overall effect: Z =	1058 .16, df = 29 (P < 0.00001); l ² = 3.48 (P = 0.0005) .ces: Chi ² = 60.62, df = 13 (P <	84%	100.0%	-0.16 [-0.25, -0.07] -10	-5 0 5 10 Favours [ADHD] Favours [control]

FIGURE 9 | Sensitivity analysis after removing heterogeneous studies of relative abundance of Genus in the Gut Microbiota of ADHD Compared with HCs. Cl, confidence interval; SMD, standardized mean difference.

TABLE 4 | Summary of the outcomes of the included studies on microbiota profiles (alpha and beta diversity) and gut microbiota taxa.

	α -diversity β -diversity		Phylum	Family	Genus	increased
		ces				decreased
S S S		stanc listan nce e		ceae ceae ae ae	2 es ella m	significant difference
	dex ection dex		eria eria eria cob	cca cca cca cca cca cca	ts - 9 ide nide s s ter ter ter ter ter ter ter ter	no difference
	0 l qs l ni n i ni n	Trac Frac S d S d	oute act act nici	ona ona ona llac bira occo dac	ella cccu terco bba bba a S a S a bba nell nell nell nell nacre cter tria	not mentioned
	Observed OTUs Observed species Chao1 index Shannon index Simnson index	weighted UniFrac distances unweighted UniFrac distances Bray–Curtis distance Jaccard distance	Firmicutes Bacteroidetes Actinobacteria Proteobacteria Verrucomicrobia	Aucangenaceae Peptostreptococcaceae Porphyromonadaceae Veillonellaceae Rikenellaceae Lachnospiraceae Ruminococcaceae Bacteroidaceae	Prevotella_9 Coprococcus_2 Parabacteroides Phascolarctobacterium Escherichia Shigella Alistipes Sutterella Veillonella Veillonella Odoribacter Bacteroides Bifidobacterium Dialister Blautia	
Szopinska-Tokov 2020						
Prehn-Kristensen 2018a						
Wan 2020						
Wang 2020						
Aart 2017						
Jiang 2018						
Richarte 2021						
Zhou 2021						
Our meta-analysis						

Study references: Szopinska-Tokov et al. (15), Prehn-Kristensen (11), Wan et al. (14), Wang et al. (2020), Aarts et al. (10), Jiang et al. (12), Richarte et al. (16), Zhou et al. (17).

biomarker for ADHD. But there still needs more evidence to verify because of the limited number of studies currently.

Blautia belongs to the Lachnospiraceae family, Firmicutes phylum, and contains 20 kinds of species as of now (21). Several recent studies have indicated that Blautia is associated with host dysfunctions, such as depression (22, 23), obesity (24, 25), atherosclerosis (26, 27), diabetes (28), and cancer (29), and we now extend these findings to ADHD. This may relate to the functions of physiological of Blautia. First, Blautia can upregulate T cells (30) in the gut and produce short-chain fatty acids (18) as well as influence the ratio of IFN- γ to IL-4 or TNF- α to IL-4 (31) to achieve anti-inflammatory effects (32). Second, Blautia can produce bacteriocins (33), a kind of secondary metabolite whose function is to prevent the infection of opportunistic pathogens (34). Third, one of the metabolites of Blautia is acetic acid, which may modulate other gut microbiota by increasing IgA and changing the capacity of the IgA pool to bind to specific microorganisms (35) and cause a change in gut stability. As inflammation and immunity are substantial etiologies of ADHD, Blautia is a possible biomarker of ADHD.

Another point to highlight is that several studies have demonstrated that the use of probiotics or prebiotics may improve ADHD symptoms (19, 36), but we did not conduct an analysis, as most studies included in this meta-analysis did not report on this topic clearly.

In fact, a few limitations should be considered in the metaanalysis. First, the small number of studies and the low to medium sample sizes of each study made the statistical power limited. Other limitations should take into account are geographical location, age, the use of medication, and diet pattern, which may affect outcomes, suggesting that further clinical studies need to be improved to consider these factors. In addition to the reasons described above, a few other factors may also cause high heterogeneity. We did not conduct subgroup analyses of sampling method, sampling time, sequencing, or analysis pipelines because of the limitations of the included literature. However, we performed sensitivity analysis by excluding one or two inappropriate articles when the heterogeneity was high.

REFERENCES

- Willcutt EG. The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review. *Neurotherapeutics* (2012) 9(3):490–9. doi: 10.1007/s13311-012-0135-8
- Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the First Genome-Wide Significant Risk Loci for Attention Deficit/Hyperactivity Disorder. *Nat Genet* (2019) 51(1):63–75. doi: 10.1038/ s41588-018-0269-7
- Sciberras E, Mulraney M, Silva D, Coghill D. Prenatal Risk Factors and the Etiology of ADHD-Review of Existing Evidence. *Curr Psychiatry Rep* (2017) 19(1):1. doi: 10.1007/s11920-017-0753-2
- Cortese S, Sun S, Zhang J, Sharma E, Chang Z, Kuja-Halkola R, et al. Association Between Attention Deficit Hyperactivity Disorder and Asthma: A Systematic Review and Meta-Analysis and a Swedish Population-Based Study. *Lancet Psychiatry* (2018) 5(9):717–26. doi: 10.1016/S2215-0366(18)30224-4
- Liu X, Dalsgaard S, Munk-Olsen T, Li J, Wright RJ, Momen NC. Parental Asthma Occurrence, Exacerbations and Risk of Attention-Deficit/ Hyperactivity Disorder. *Brain Behav Immun* (2019) 82:302–8. doi: 10.1016/ j.bbi.2019.08.198

CONCLUSION

This is the first meta-analysis to assess gut microbiota and ADHD to date. We found a higher Shannon index and *Blautia* in ADHD patients than in HCs, but there were no significant differences at the phylum and family levels. The result for *Blautia* survived the sensitivity analysis. Further clinical studies need to be taken to consider factors such as geographical location, medication use, diet pattern, sequencing and analysis pipelines to validate these results.

AUTHOR CONTRIBUTIONS

LY took responsibility for the integrity of the data and the accuracy of the data analysis. Study concept, design and supervision: LY and ZZ. Data extraction, analysis and interpretation: all authors. Drafting of the manuscript: NW and XG. Revision of the manuscript: LY and ZZ. All authors interpreted the results, and approved the final version of this article.

FUNDING

This study received funding from National Natural Science Foundation of China (grant numbers: 81873803, 81761128035), Beijing Municipal Science and Technology Commission (Z181100001518005).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022. 838941/full#supplementary-material

- van der Schans J, Aikman B, de Vries TW, Hoekstra PJ, Hak E. Association Between Attention-Deficit/Hyperactivity Disorder and Asthma Among Adults: A Case-Control Study. *Chest* (2017) 151(6):1406–7. doi: 10.1016/ j.chest.2017.03.052
- Boonchooduang N, Louthrenoo O, Chattipakorn N, Chattipakorn SC. Possible Links Between Gut-Microbiota and Attention-Deficit/ Hyperactivity Disorders in Children and Adolescents. *Eur J Nutr* (2020) 59 (8):3391–403. doi: 10.1007/s00394-020-02383-1
- Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data: The PRISMA-IPD Statement. *JAMA* (2015) 313(16):1657–65. doi: 10.1001/jama.2015.3656
- Stang A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. *Eur J Epidemiol* (2010) 25(9):603–5. doi: 10.1007/s10654-010-9491-z
- Aarts E, Ederveen T, Naaijen J, Zwiers MP, Boekhorst J, Timmerman HM, et al. Gut Microbiome in ADHD and its Relation to Neural Reward Anticipation. *PloS One* (2017) 12(9):e183509. doi: 10.1371/journal.pone.0183509
- 11. Prehn-Kristensen A, Zimmermann A, Tittmann L, Lieb W, Schreiber S, Baving L, et al. Reduced Microbiome Alpha Diversity in Young Patients

With ADHD. PloS One (2018) 13(7):e200728. doi: 10.1371/ journal.pone.0200728

- Jiang HY, Zhou YY, Zhou GL, Li YC, Yuan J, Li XH, et al. Gut Microbiota Profiles in Treatment-Naïve Children With Attention Deficit Hyperactivity Disorder. *Behav Brain Res* (2018) 347:408–13. doi: 10.1016/j.bbr.2018.03.036
- Wang LJ, Yang CY, Chou WJ, Lee MJ, Chou MC, Kuo HC, et al. Gut Microbiota and Dietary Patterns in Children With Attention-Deficit/ Hyperactivity Disorder. *Eur Child Adolesc Psychiatry* (2020) 29(3):287–97. doi: 10.1007/s00787-019-01352-2
- 14. Wan L, Ge WR, Zhang S, Sun YL, Wang B, Yang G. Case-Control Study of the Effects of Gut Microbiota Composition on Neurotransmitter Metabolic Pathways in Children With Attention Deficit Hyperactivity Disorder. Front Neurosci (2020) 14:127. doi: 10.3389/fnins.2020.00127
- Szopinska-Tokov J, Dam S, Naaijen J, Konstanti P, Rommelse N, Belzer C, et al. Investigating the Gut Microbiota Composition of Individuals With Attention-Deficit/Hyperactivity Disorder and Association With Symptoms. *Microorganisms* (2020) 8(3):1358. doi: 10.3390/microorganisms8030406
- Richarte V, Sánchez-Mora C, Corrales M, Fadeuilhe C, Vilar-Ribó L, Arribas L, et al. Gut Microbiota Signature in Treatment-Naïve Attention-Deficit/ Hyperactivity Disorder. *Transl Psychiatry* (2021) 11(1):382. doi: 10.1038/ s41398-021-01504-6
- 17. Zhou G, Yu R, Ahmed T, Jiang H, Zhang M, Lv L, et al. Biosynthesis and Characterization of Zinc Oxide Nanoparticles and Their Impact on the Composition of Gut Microbiota in Healthy and Attention-Deficit Hyperactivity Disorder Children. *Front Microbiol* (2021) 12:700707. doi: 10.3389/fmicb.2021.700707
- Wang B, Kong Q, Li X, Zhao J, Zhang H, Chen W, et al. A High-Fat Diet Increases Gut Microbiota Biodiversity and Energy Expenditure Due to Nutrient Difference. *Nutrients* (2020) 12(10):3197. doi: 10.3390/nu12103197
- Kalenik A, Kardaś K, Rahnama A, Sirojć K, Wolańczyk T. Gut Microbiota and Probiotic Therapy in ADHD: A Review of Current Knowledge. Prog Neuropsychopharmacol Biol Psychiatry (2021) 110:110277. doi: 10.1016/ j.pnpbp.2021.110277
- Lacorte E, Gervasi G, Bacigalupo I, Vanacore N, Raucci U, Parisi P. A Systematic Review of the Microbiome in Children With Neurodevelopmental Disorders. *Front Neurol* (2019) 10:727. doi: 10.3389/fneur.2019.00727
- Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, et al. Blautia-A New Functional Genus With Potential Probiotic Properties? *Gut Microbes* (2021) 13(1):1–21. doi: 10.1080/19490976.2021.1875796
- Cheung SG, Goldenthal AR, Uhlemann AC, Mann JJ, Miller JM, Sublette ME. Systematic Review of Gut Microbiota and Major Depression. *Front Psychiatry* (2019) 10:34. doi: 10.3389/fpsyt.2019.00034
- Yang J, Zheng P, Li Y, Wu J, Tan X, Zhou J, et al. Landscapes of Bacterial and Metabolic Signatures and Their Interaction in Major Depressive Disorders. Sci Adv (2020) 6(49):eaba8555. doi: 10.1126/sciadv.aba8555
- Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, et al. Structural Alteration of Gut Microbiota During the Amelioration of Human Type 2 Diabetes With Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: A Multicenter, Randomized, Open Label Clinical Trial. *Mbio* (2018) 9(3): e02392–17. doi: 10.1128/mBio.02392-17
- Kong C, Gao R, Yan X, Huang L, Qin H. Probiotics Improve Gut Microbiota Dysbiosis in Obese Mice Fed a High-Fat or High-Sucrose Diet. *Nutrition* (2019) 60:175–84. doi: 10.1016/j.nut.2018.10.002
- 26. Wu M, Yang S, Wang S, Cao Y, Zhao R, Li X, et al. Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoE-/- Mice. *Front Pharmacol* (2020) 11:223. doi: 10.3389/fphar.2020.00223

- 27. Yue C, Li M, Li J, Han X, Zhu H, Yu G, et al. Medium-, Long- and Medium-Chain-Type Structured Lipids Ameliorate High-Fat Diet-Induced Atherosclerosis by Regulating Inflammation, Adipogenesis, and Gut Microbiota in ApoE(-/-) Mice. *Food Funct* (2020) 11(6):5142–55. doi: 10.1039/d0fo01006e
- Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of Gut Microbiota in Type 2 Diabetes Pathophysiology. *Ebiomedicine* (2020) 51:102590. doi: 10.1016/j.ebiom.2019.11.051
- Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, et al. Relating the Gut Metagenome and Metatranscriptome to Immunotherapy Responses in Melanoma Patients. *Genome Med* (2019) 11(1):61. doi: 10.1186/s13073-019-0672-4
- Xie Y, Sun J, Wei L, Jiang H, Hu C, Yang J, et al. Altered Gut Microbiota Correlate With Different Immune Responses to HAART in HIV-Infected Individuals. *BMC Microbiol* (2021) 21(1):11. doi: 10.1186/s12866-020-02074-1
- Benítez-Páez A, Gómez DPE, López-Almela I, Moya-Pérez Á, Codoñer-Franch P, Sanz Y. Depletion of Blautia Species in the Microbiota of Obese Children Relates to Intestinal Inflammation and Metabolic Phenotype Worsening. *Msystems* (2020) 5(2):e00857–19. doi: 10.1128/mSystems. 00857-19
- 32. Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, et al. Intestinal Microbiota-Derived Short-Chain Fatty Acids Regulation of Immune Cell IL-22 Production and Gut Immunity. *Nat Commun* (2020) 11(1):4457. doi: 10.1038/s41467-020-18262-6
- 33. Perez M, Ntemiri A, Tan H, Harris H, Roager HM, Ribière C, et al. A Synthetic Consortium of 100 Gut Commensals Modulates the Composition and Function in a Colon Model of the Microbiome of Elderly Subjects. *Gut Microbes* (2021) 13(1):1–19. doi: 10.1080/19490976.2021.1919464
- 34. Kim SG, Becattini S, Moody TU, Shliaha PV, Littmann ER, Seok R, et al. Microbiota-Derived Lantibiotic Restores Resistance Against Vancomycin-Resistant Enterococcus. *Nature* (2019) 572(7771):665–9. doi: 10.1038/ s41586-019-1501-z
- Takeuchi T, Miyauchi E, Kanaya T, Kato T, Nakanishi Y, Watanabe T, et al. Acetate Differentially Regulates IgA Reactivity to Commensal Bacteria. *Nature* (2021) 595(7868):560–4. doi: 10.1038/s41586-021-03727-5
- 36. Rosi E, Grazioli S, Villa FM, Mauri M, Gazzola E, Pozzi M, et al. Use of Non-Pharmacological Supplementations in Children and Adolescents With Attention Deficit/Hyperactivity Disorder: A Critical Review. Nutrients (2020) 12(6):1573. doi: 10.3390/nu12061573

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Gao, Zhang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.